Information Provided By: 
Fly News Breaks for October 18, 2019
FLDM
Oct 18, 2019 | 05:47 EDT
UBS analyst Dan Brennan upgraded Fluidigm to Buy from Neutral with a price target of $7, down from $14. The stock's 50% decline year-to-date brings an attractive entry point given the company's ~10% revenue growth outlook, "solid" mass cytometry franchise, and improved balance sheet, Brennan tells investors in a research note. He believes stabilizing the microfluidics declines and having more quarterly consistency are keys to the stock turning around.
News For FLDM From the Last 2 Days
There are no results for your query FLDM
